Rezolute, Inc.
NASDAQ:RZLT
Overview | Financials
Company Name | Rezolute, Inc. |
Symbol | RZLT |
Currency | USD |
Price | 4.9 |
Market Cap | 283,921,190 |
Dividend Yield | 0% |
52-week-range | 0.9 - 6.186 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Nevan Charles Elam J.D. |
Website | https://www.rezolutebio.com |
An error occurred while fetching data.
About Rezolute, Inc.
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD